EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy

Salomé S Pinho, Matthew S Macauley, Heinz Läubli

Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e012391

DOI: 10.1136/jitc-2025-012391 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.06.2025. Verfasst von Salomé S Pinho und 2 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Institute for Research and Innovation in Health, University of Porto, Porto, Portugal heinz.laeubli@unibas.ch salomep@i3s.up.pt macauley@ualber…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Porto Comprehensive Cancer Center Raquel Seruca, CIHR, Mizutani Foundation for Glycoscience.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy, including immune checkpoint inhibition, has transformed the prognosis of many patients with cancer. However, most patients have primary or secondary resistant tumors to currently available cancer immunotherapies. Changes in glycosylation of malignant cells and in the tumor microenvironment are a new target to overcome resistance to current cancer immunotherapies and to improve the outcome of patients. Here, we summarize how changes in glycosylation in cancer have functional consequences on the immune system. Such changes can be directly targeted with drugs. Moreover, they can mediate immune-suppressive effects. For example, increased sialylation can enhance interactions with immune-inhibitory Siglec receptors, and galectin-mediated interactions can modulate immune responses in the context of cancer. Finally, we provide an overview of approaches to therapeutically target these changes for the improvement of cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsImmune Checkpoint InhibitorsHumansGlycosylationTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

Immune Checkpoint InhibitorImmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • i3S - Institute for Research and Innovation in Health, University of Porto, Porto, Portugal heinz.laeubli@unibas.ch salomep@i3s.up.pt macauley@ualberta.ca.
  • Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada heinz.laeubli@unibas.ch salomep@i3s.up.pt macauley@ualberta.ca.
  • Universitätsspital Basel and University of Basel, Basel, Switzerland heinz.laeubli@unibas.ch salomep@i3s.up.pt macauley@ualberta.ca.

Förderung

  • Porto Comprehensive Cancer Center Raquel Seruca
  • CIHR
  • Mizutani Foundation for Glycoscience
  • Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Canadian Glycomics Network
  • Portuguese Society of Digestive Endoscopy

Zitieren

APA

Pinho, S. S., Macauley, M. S., & Läubli, H. (2025). Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy. Journal for ImmunoTherapy of Cancer, 13(6), e012391. https://doi.org/10.1136/jitc-2025-012391

Vancouver

Pinho SS, Macauley MS, Läubli H. Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy. Journal for ImmunoTherapy of Cancer. 2025;13(6):e012391. doi:10.1136/jitc-2025-012391

BibTeX
@article{Pinho2025,
  author = {Pinho, Salomé S and Macauley, Matthew S and Läubli, Heinz},
  title = {Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {e012391},
  doi = {10.1136/jitc-2025-012391}
}
Kostenlos starten →